Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Multi-pathway cellular analysis of compound selectivity.

Hancock MK, Lebakken CS, Wang J, Bi K.

Mol Biosyst. 2010 Oct;6(10):1834-43. doi: 10.1039/c003669b. Epub 2010 Jun 30.

PMID:
20593073
3.

Single cell network profiling (SCNP): mapping drug and target interactions.

Covey TM, Putta S, Cesano A.

Assay Drug Dev Technol. 2010 Jun;8(3):321-43. doi: 10.1089/adt.2009.0251.

PMID:
20158439
4.

The CellCard System: a novel approach to assessing compound selectivity for lead prioritization of G protein-coupled receptors.

Beske O, Goldbard S, Turpin P.

Comb Chem High Throughput Screen. 2005 Jun;8(4):293-9.

PMID:
16101005
5.
6.

Multiplexing of pathway-specific beta-lactamase reporter gene assays by optical coding with Qtracker nanocrystals.

Machleidt T, Whitney P, Bi K.

J Biomol Screen. 2009 Aug;14(7):845-52. doi: 10.1177/1087057109335742. Epub 2009 Jun 5.

PMID:
19502565
7.

High-throughput biochemical kinase selectivity assays: panel development and screening applications.

Card A, Caldwell C, Min H, Lokchander B, Hualin Xi, Sciabola S, Kamath AV, Clugston SL, Tschantz WR, Leyu Wang, Moshinsky DJ.

J Biomol Screen. 2009 Jan;14(1):31-42. doi: 10.1177/1087057108326663. Epub 2008 Dec 10.

PMID:
19073965
8.

High throughput screening methodologies classified for major drug target classes according to target signaling pathways.

Kool J, Lingeman H, Niessen W, Irth H.

Comb Chem High Throughput Screen. 2010 Jul;13(6):548-61. Review.

PMID:
20429869
9.
10.

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW.

Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98. Review.

PMID:
12191602
11.

Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.

Dobbin E, Graham C, Corrigan PM, Thomas KG, Freeburn RW, Wheadon H.

Exp Hematol. 2009 Jan;37(1):111-121. doi: 10.1016/j.exphem.2008.09.012.

PMID:
19100521
13.

Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.

Pappano WN, Jung PM, Meulbroek JA, Wang YC, Hubbard RD, Zhang Q, Grudzien MM, Soni NB, Johnson EF, Sheppard GS, Donawho C, Buchanan FG, Davidsen SK, Bell RL, Wang J.

BMC Cancer. 2009 Sep 4;9:314. doi: 10.1186/1471-2407-9-314.

14.

The JAK-STAT pathway: a therapeutic target in hematological malignancies.

Ferrajoli A, Faderl S, Ravandi F, Estrov Z.

Curr Cancer Drug Targets. 2006 Dec;6(8):671-9. Review.

PMID:
17168672
15.

High-throughput kinase profiling as a platform for drug discovery.

Goldstein DM, Gray NS, Zarrinkar PP.

Nat Rev Drug Discov. 2008 May;7(5):391-7. doi: 10.1038/nrd2541. Review.

PMID:
18404149
16.

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Gollob JA, Wilhelm S, Carter C, Kelley SL.

Semin Oncol. 2006 Aug;33(4):392-406. Review.

PMID:
16890795
17.

JAK-2 mutations and their relevance to myeloproliferative disease.

Levine RL, Gilliland DG.

Curr Opin Hematol. 2007 Jan;14(1):43-7. Review.

PMID:
17133099
18.

Comparative analysis of the JAK/STAT signaling through erythropoietin receptor and thrombopoietin receptor using a systems approach.

Won HH, Park I, Lee E, Kim JW, Lee D.

BMC Bioinformatics. 2009 Jan 30;10 Suppl 1:S53. doi: 10.1186/1471-2105-10-S1-S53.

19.

Design of allele-specific inhibitors to probe protein kinase signaling.

Bishop AC, Shah K, Liu Y, Witucki L, Kung C, Shokat KM.

Curr Biol. 1998 Feb 26;8(5):257-66.

20.

Functional interrogation of the kinome using nucleotide acyl phosphates.

Patricelli MP, Szardenings AK, Liyanage M, Nomanbhoy TK, Wu M, Weissig H, Aban A, Chun D, Tanner S, Kozarich JW.

Biochemistry. 2007 Jan 16;46(2):350-8.

PMID:
17209545

Supplemental Content

Support Center